Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490287 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0692-4 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0692-4 | ||
| 245 | 0 | 0 | |a Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience |h [Elektronische Daten] |c [Keishi Makino, Hideo Nakamura, Taku-ichiro Hide, Jun-ichiro Kuroda, Shigetoshi Yano, Jun-ichi Kuratsu] |
| 520 | 3 | |a Abstract : Background: This retrospective single-center study assessed the feasibility, outcomes, and side-effects of high-dose methotrexate (HD-MTX) plus procarbazine in the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL). Methods: Ninety-one patients diagnosed with PCNSL between January 2001 and December 2011 were treated with HD-MTX plus procarbazine. To reduce neurotoxicity in patients aged ≥60years, only those not responding to chemotherapy and patients with relapse underwent whole-brain irradiation. Results: All 91 consecutive patients were scheduled to receive HD-MTX. Their median age was 66years (range 32-88years) and their median Karnofsky performance score was 40 (range 20-100). While 56 patients (61.5%) completed 3 cycles of HD-MTX chemotherapy and 48 (52.7%) showed a complete response, treatment was stopped in 11 patients (12.1%) due to toxicity. The median overall survival and progression-free survival were 40.6 and 11.7months, respectively. Overall survival was significantly improved in patients who completed 3 cycles of chemotherapy compared with those did not (56.4 vs 24.0months; p=0.013 by univariate and p=0.022 by multivariate analysis). Conclusions: Initial treatment with HD-MTX plus procarbazine was effective in patients with PCNSL. Completion of 3 cycles of HD-MTX chemotherapy was a significant independent prognostic factor for patient survival. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Primary central nervous system lymphoma |2 nationallicence | |
| 690 | 7 | |a High-dose methotrexate |2 nationallicence | |
| 690 | 7 | |a Chemotherapy |2 nationallicence | |
| 690 | 7 | |a Retrospective study |2 nationallicence | |
| 690 | 7 | |a Prognostic impact |2 nationallicence | |
| 700 | 1 | |a Makino |D Keishi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Nakamura |D Hideo |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Hide |D Taku-ichiro |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Kuroda |D Jun-ichiro |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Yano |D Shigetoshi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Kuratsu |D Jun-ichi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 29-34 |x 1341-9625 |q 20:1<29 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0692-4 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0692-4 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Makino |D Keishi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nakamura |D Hideo |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hide |D Taku-ichiro |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kuroda |D Jun-ichiro |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yano |D Shigetoshi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kuratsu |D Jun-ichi |u Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 29-34 |x 1341-9625 |q 20:1<29 |1 2015 |2 20 |o 10147 | ||